[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Genrix (Shanghai) Biopharmaceutical Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":266},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,45,67,90,115,137,160,180,200,221,241],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100642534","phase-1-a-clinical-trial-of-multiple-doses-of-gr2301-injection-in-healthy-adult-trial-participants-in-china-100642534",false,"NCT07647224","A Clinical Trial of Multiple Doses of GR2301 Injection in Healthy Adult Trial Participants in China.","A Randomized, Double-blind, Placebo-controlled Phase Ib Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity Profiles of Multiple Doses of GR2301 Injection in Healthy Adult Trial Participants in China.","Main Inclusion Criteria:\n\n1. BMI 19.0-28.0 kg\u002Fm², with male subjects weighing ≥50.0 kg and female subjects weighing ≥45.0 kg；\n2. Understand and comply with the requirements of the clinical protocol, voluntarily participate in the clinical trial, and sign the informed consent form.\n\nMain Exclusion Criteria:\n\n1. A history of past or current conditions involving the nervous system, cardiovascular system, urinary system, digestive system, respiratory system, endocrine system, metabolic system, or other clearly documented medical conditions, which the investigator deems may pose a risk to the subject's safety or interfere with the conduct, progress, or completion of the trial.\n2. History of drug use or substance abuse, or positive urine drug screening prior to enrollment.\n3. Pregnant and breastfeeding women.",true,"ALL","18 Years","45 Years",{"count":21,"type":22},36,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This is a randomized, double-blind, placebo-controlled Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and immunogenicity characteristics of GR2301 injection in healthy adult subjects in China. The Multiple doses will be gradually escalated.",[28,29],"Multiple Dose","Healthy Adult Participants",[31],"IL15","NOT_YET_RECRUITING","2026-06-09",{"date":35,"type":36},"2026-06-15","ACTUAL",{"date":38,"type":22},"2026-06",{"date":40,"type":22},"2027-07",{"name":42,"class":43},"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","INDUSTRY",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":64,"leadSponsor":66,"locationsCount":4},"100641939","phase-1-a-clinical-trial-of-multiple-doses-of-gr2301-injection-combined-with-phototherapy-in-trial-participants-with-vitiligo-100641939","NCT07647237","A Clinical Trial of Multiple Doses of GR2301 Injection Combined With Phototherapy in Trial Participants With Vitiligo","A Randomized, Double-blind, Placebo-controlled Phase Ib\u002FII Clinical Trial of Multiple Subcutaneous Injections of GR2301 in Combination With Phototherapy to Evaluate the Tolerability, Safety, Pharmacokinetics, and Preliminary Efficacy in Trial Participants With Vitiligo","GREVIT","Main Inclusion Criteria:\n\n1. Meet the clinical diagnosis of non-segmental vitiligo at screening visit and baseline visit, and meet the following criteria: clinical diagnosis of non-segmental vitiligo for at least 3 months at screening visit; facial affected BSA ≥0.5% and total body affected BSA ≥3% at screening visit and baseline visit; F-VASI and T-VASI scores meet the criteria at screening visit and baseline visit.\n2. Able to understand and comply with the requirements of the clinical protocol, voluntarily participate in the clinical trial, and provide signed written informed consent by the trial participant or their legally authorized representative.\n\nMain Exclusion Criteria:\n\n1. Vitiligo-related medical conditions and other dermatologic diseases\u002Fconditions.\n2. Prior permanent tattooing or grafting within the vitiligo lesions.\n3. Have absolute contraindications to phototherapy; or have relative contraindications to phototherapy (as comprehensively judged by the investigator).\n4. Are unwilling or unable to comply with the permitted and prohibited concomitant medications\u002Ftreatment specifications of this trial, and cannot meet the protocol-required washout period for medications\u002Ftreatments prior to randomization.\n5. Have a serious underlying disease that, in the investigator's opinion, may pose a safety risk to the trial participant if enrolled in the clinical trial.","65 Years",{"count":55,"type":22},116,[25,57],"PHASE2","This is a randomized, double-blind, placebo-controlled Phase Ib\u002FII clinical trial of multiple subcutaneous injections of GR2301 in combination with phototherapy to evaluate the tolerability, safety, pharmacokinetics, and preliminary efficacy in trial participants with vitiligo. The trial will be conducted in two stages: a dose-escalation stage (Phase Ib) and an expansion cohort stage (Phase II).",[60],"Vitiligo",[31],{"date":35,"type":36},{"date":38,"type":22},{"date":65,"type":22},"2028-12",{"name":42,"class":43},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":23,"phases":76,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":44},"100627712","phase-3-a-study-of-gr1803-injection-versus-daratumumab-pomalidomide-and-dexamethasone-dpd-in-participants-with-relapsed-or-refractory-multiple-myeloma-100627712","NCT07452198","A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma","A Phase 3, Multicenter, Open-Label, Randomized Study Comparing GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy Including Lenalidomide and Proteasome Inhibitors","Inclusion Criteria:\n\n* Have an eastern cooperative oncology group (ECOG) performance status score of 0, 1, or 2 at screening and baseline.\n* Diagnosed as multiple myeloma according to the diagnostic criteria of the International Myeloma Working Group (IMWG) diagnostic criteria.\n* Received 1 to 3 prior line(s) of antimyeloma therapy including a proteasome inhibitor (PI) and lenalidomide; a. participants who have received only 1 line of prior line of antimyeloma therapy must be lenalidomide refractory. Stable disease or progression on or within 60 days of the last dose of lenalidomide given as maintenance will meet this criterion.\n* Documented evidence of progressive or stable disease based on investigator's determination of response by IMWG criteria on or after their last regimen.\n* Measurable disease at screening and baseline as defined by any of the following: 1) serum M-protein level greater than or equal to (\\>=) 5 gram per liter (g\u002FL); or 2) urine M-protein level \\>=200 milligrams (mg)\u002F24 hours; or 3) serum immunoglobulin free light chain \\>=100 mg\u002FL and abnormal serum immunoglobulin kappa lambda free light chain ratio.\n* Have clinical laboratory values within the specified range.\n* Have an understanding of and comply with the clinical trial protocol requirements, voluntarily participate in the clinical trial, and sign the informed consent form.\n\nExclusion Criteria:\n\n* Plasma cell leukemia, Waldenström's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes), or amyloidosis (including primary and secondary).\n* History or clinical signs of central nervous system involvement or meningeal involvement of multiple myeloma .\n* Received any prior B cell maturation antigen (BCMA)-directed therapy.\n* Has disease that is considered refractory or intolerant to an anti-cluster of differentiation 38 (CD38) targeted therapy or Pomalidomide.\n* Prior antitumor therapy, within 21 days (PI 、IMiDs or radiotherapy within 14 days, clinical trial vaccine within 28 days, Gene modified adoptive cell therapy within 3 months, allogeneic stem cell transplantation within 6 months, autologous stem cell transplantation within 12 weeks) prior to first dose of study drug.\n* Received a cumulative dose of corticosteroids equivalent to \\>=140 mg of prednisone within 14 days prior to first dose of study drug.\n* Grade \\>= 2 peripheral neuropathy at screening.\n* History of Guillain Barre Syndrome (GBS) or variant GBS.\n* The following medical conditions: active infecion, human immunodeficiency virus (HIV) infection, hepatitis B or C infection, Syphilis infection, thromboembolic events or cerebrovascular events less than or equal to (\\\u003C=) 6 m, seizure attacks less than or equal to (\\\u003C=) 6 m.\n* Active malignancies other than relapsed\u002Frefractory multiple myeloma within 3 years prior to screening.\n* Active autoimmune disease or history of autoimmune disease.\n* Received a live, attenuated vaccine within 4 weeks before first dose of study drug.\n* Have major surgery within 2 weeks before first dose of study drug.\n* Contraindications or life-threatening allergies, hypersensitivity, or intolerance to any study drug or its excipients.\n* Pregnant, lactating female.",{"count":75,"type":22},358,[77],"PHASE3","The purpose of this study is to compare the efficacy of GR1803 Injection with daratumumab in combination with pomalidomide and dexamethasone (DPd).",[80],"Multiple Myeloma","RECRUITING","2026-03-23",{"date":84,"type":36},"2026-03-25",{"date":86,"type":36},"2026-03-09",{"date":88,"type":22},"2030-03",{"name":42,"class":43},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":23,"phases":100,"briefSummary":101,"conditions":102,"keywords":105,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":44},"100619702","phase-1-a-study-of-gr1803-in-systemic-lupus-erythematosus-100619702","NCT07348055","A Study of GR1803 in Systemic Lupus Erythematosus","A Phase Ib\u002FIIa Clinical Trial Evaluating the Safety, Tolerability, and Efficacy of GR1803 Injection in Subjects With Systemic Lupus Erythematosus","Inclusion Criteria:\n\n* comfirmed diagnosis of systemic lupus erythematosus\n* SLEDAI-2K≥6分\n* written informed consent and ability to comply with protocol requirements\n* have received adequate dose of glucocorticoids, antimalarials, immunosuppressants for 3 months\n\nExclusion Criteria:\n\n* with unstable acute and chronic diseases\n* active infection\n* history of malignant tumor within 5 years","60 Years",{"count":99,"type":22},44,[25,57],"to evaluate the safety and efficacy of GR1803 in the treatment of patients with systemic lupus erythematosus",[103,104],"Systemic Lupus Erthematosus","Auto Immune Disease",[106,107],"BCMA\u002FCD3 Bispecific Antibody","systemic lupus erythematosus",{"date":109,"type":36},"2026-03-10",{"date":111,"type":36},"2026-02-02",{"date":113,"type":22},"2027-12-01",{"name":42,"class":43},{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":17,"minAge":122,"maxAge":18,"enrollmentInfo":123,"targetDuration":4,"studyType":23,"phases":125,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":44},"100608261","phase-3-a-study-of-gr1802-injection-in-patients-with-seasonal-allergic-rhinitis-100608261","NCT07199257","A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis.","A Multicenter Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of GR1802 Injection in Combination With Background Therapy in Patients With Seasonal Allergic Rhinitis.","Main Inclusion Criteria:\n\n1. Voluntarily sign the informed consent form.\n2. Seasonal allergic rhinitis has been prevalent for at least 2 years.Positive for allergens associated with seasonal allergic rhinitis.\n3. Poor control of seasonal allergic rhinitis with nasal glucocorticoids or other therapeutic agents during the same pollen season in the past.\n4. Weight≥30kg.\n5. Symptom severity scores for the season met the enrollment criteria.\n\nMain Exclusion Criteria:\n\n1. Other nasal comorbidities or co-morbidities\u002Fstates that may be present at the time of screening that affect efficacy determination.\n2. Subjects whose allergen exposures in their home or work environments may be expected to change significantly during the trial period.\n3. Subjects with poorly controlled recent asthma conditions.\n4. Presence of current or past history of infection of special concern, e.g., active tuberculosis, helminthic infections, severe herpes virus infections, etc.\n5. Previous use of anti-interleukin 4 receptor alpha subunit (IL4Rα) monoclonal antibody.\n6. Have a serious underlying medical condition that, in the opinion of the investigator, may pose a risk to subject safety by participation in a clinical trial.","12 Years",{"count":124,"type":22},144,[77],"Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies.",[128],"Allergic Rhinitis, Seasonal","2025-09-22",{"date":131,"type":36},"2025-09-30",{"date":133,"type":22},"2025-09-25",{"date":135,"type":22},"2027-07-31",{"name":42,"class":43},{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":144,"targetDuration":4,"studyType":23,"phases":146,"briefSummary":147,"conditions":148,"keywords":150,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":154,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":44},"100608262","phase-1-a-study-to-evaluate-the-safety-immunogenicity-and-pharmacokinetics-of-gr2303-in-healthy-adult-100608262","NCT07199270","A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2303 in Healthy Adult","A Randomized, Double-blind, Placebo-controlled of GR2303 Injection in Healthy Adult Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Pharmacologic of GR2303","Inclusion Criteria:\n\n1. Healthy adult subjects\n2. Signed informed consent\n\nExclusion Criteria:\n\n1. History or presence of any clinically significant organ system disease that could interfere with the objectives of the study or the safety of the subjects.\n2. Prior use of drug targeting TNF-like cytokine 1A\n3. history of malignant tumor\n4. psitive results for Hepatitis B surface antigen (HBsAg), anti Hepatitis C antibody (HCV Ab) or human immunodeficiency virus (HIV)",{"count":145,"type":22},64,[25],"he goal this clinical trail is to evaluate the safety、Pharmacokinetic and immunogenicity of GR2303 injection。 Subjects will be enrolled in different groups in sequential order, and within each group will be randomly assigned to receive either GR2303 injection or placebo administration, with each Subjects will be enrolled in only one of these groups",[149],"Health Adult Subjects",[151,152,153],"Inflamatory bowel disease","phase 1","GR2303",{"date":131,"type":36},{"date":156,"type":36},"2025-09-18",{"date":158,"type":22},"2026-12-16",{"name":42,"class":43},{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":166,"targetDuration":4,"studyType":23,"phases":167,"briefSummary":168,"conditions":169,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":44},"100607604","phase-1-a-study-to-evaluate-the-safety-of-gr2301-injection-in-healthy-volunteers-100607604","NCT07190716","A Study to Evaluate the Safety of GR2301 Injection in Healthy Volunteers.","A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Pharmacodynamic Characteristics of a Single Dose of GR2301 Injection in Healthy Adult Subjects in China.",{"count":21,"type":22},[25],"This is a randomized, double-blind, placebo-controlled Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary pharmacodynamic characteristics of GR2301 injection in healthy adult subjects in China.The GR2301 injection dosage will be gradually increased. All healthy subjects will receive a single subcutaneous injection. Following administration, subjects will be followed for at least 16 weeks ± 7 days.",[170,171],"Single Ascending Dose","Healthy Subjects","2025-09-17",{"date":174,"type":36},"2025-09-24",{"date":176,"type":22},"2025-10-10",{"date":178,"type":22},"2026-05-30",{"name":42,"class":43},{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":23,"phases":190,"briefSummary":126,"conditions":191,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":44},"100604809","phase-3-a-study-of-il4r-monoclonal-antibody-in-patients-with-seasonal-allergic-rhinitis-100604809","NCT07154342","A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis","A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of GR1802 Injection in Combination With Background Therapy in Patients With SAR","Main Inclusion Criteria:\n\n1. Voluntarily sign the informed consent form.\n2. Seasonal allergic rhinitis has been prevalent for at least 2 years.\n3. Poor control of seasonal allergic rhinitis with nasal glucocorticoids or other therapeutic agents during the same pollen season in the past.\n4. Positive serum-specific IgE test results.\n5. Symptom severity scores for the season met the enrollment criteria.\n\nMain Exclusion Criteria:\n\n1. Other nasal comorbidities or co-morbidities\u002Fstates that may be present at the time of screening that affect efficacy determination.\n2. Subjects whose allergen exposures in their home or work environments may be expected to change significantly during the trial period.\n3. Subjects with poorly controlled recent asthma conditions.\n4. Presence of current or past history of infection of special concern, e.g., active tuberculosis, helminthic infections, severe herpes virus infections, etc.\n5. Previous use of anti-interleukin 4 receptor alpha subunit (IL4Rα) monoclonal antibody.\n6. Have a serious underlying medical condition that, in the opinion of the investigator, may pose a risk to subject safety by participation in a clinical trial.","75 Years",{"count":189,"type":22},150,[77],[128],"2025-08-26",{"date":194,"type":36},"2025-09-04",{"date":196,"type":36},"2025-08-15",{"date":198,"type":22},"2026-07-31",{"name":42,"class":43},{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":23,"phases":209,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":220},"100599935","phase-1-a-study-of-gr1803-injection-in-combination-with-anti-cd38-monoclonal-antibody-for-the-treatment-of-participants-with-multiple-myeloma-100599935","NCT07090954","A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma","An Open-Label, Multicenter, Phase Ib\u002FII Clinical Trial of GR1803 Injection in Combination With an Anti-CD38 Monoclonal Antibody Evaluating Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy in Subjects With Relapsed\u002FRefractory Multiple Myeloma Previously Treated With at Least One Line of Therapy Including Lenalidomide and a Proteasome Inhibitor","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group performance status grade of 0, 1 or 2;\n* Diagnosis of multiple myeloma；have received at least one prior line of therapy including Lenalidomide and a proteasome inhibitor.\n* Able to understand and comply with the requirements of the clinical protocol, voluntarily participate in the clinical trial, and sign informed consent.\n\nExclusion Criteria:\n\n* Plasma cell leukemia , Waldenström's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or amyloidosis.\n* Active central nervous system involvement or exhibits clinical signs of meningeal involvement of multiple myeloma.\n* Prior treatment with any BCMA-targeted therapiy.\n* Active infecion.\n* Known allergies, hypersensitivity, or intolerance to the study drug or its excipients.",{"count":208,"type":22},32,[25,57],"The purpose of this study is to identify recommended Phase 3 doses (RP3D) for treatment combination (GR1803 injection plus anti-CD38 monoclonal antibody) and to characterize the efficacy of RP3D for the treatment combination.",[80],"2025-07-21",{"date":214,"type":36},"2025-07-29",{"date":216,"type":22},"2025-08-31",{"date":218,"type":22},"2030-01-31",{"name":42,"class":43},2,{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":23,"phases":230,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":240,"locationsCount":44},"100589258","phase-2-gr1803-injection-in-patients-with-rrmm-100589258","NCT06952075","GR1803 Injection in Patients With RRMM","Single-Arm, Open, Multi-Center Phase II Clinical Trial of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of GR1803 Injection in Patients With Relapsed\u002FRefractory Multiple Myeloma Complicated by Extramedullary Plasmacytoma","Inclusion Criteria:\n\n* 1、ECOG score 0-2 2、≥18 years of age 3、Multiple myeloma must be Complicated by Extramedullary Plasmacytoma.\n\nExclusion Criteria:\n\n* 1、Prior treatment with any BCMA-targeted therapy 2、Known active CNS involvement or exhibits clinical signs of meningeal involvement of multiple myeloma 3、Known allergies, hypersensitivity, or intolerance to the study drug (teclistamab) or its excipients 4、Plasma cell leukemia , Waldenström's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or primary amyloid light-chain amyloidosis.",{"count":229,"type":22},30,[57],"All subjects will receive GR1803 injection until intolerable toxicity or investigator-assessed disease progression occurs (except in cases of disease progression due to discontinuation of the drug as a result of an adverse event) or until the subject has been administered the drug for 2 years or until the subject withdraws consent or until the investigator determines that the subject needs to be discontinued.",[233],"Multiple Myleoma","2025-04-23",{"date":236,"type":36},"2025-04-30",{"date":238,"type":36},"2025-04-24",{"date":113,"type":22},{"name":42,"class":43},{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":23,"phases":250,"briefSummary":251,"conditions":252,"keywords":254,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":265},"100564947","phase-3-a-phase-iii-clinical-trail-to-evaluate-the-efficacy-safety-pharmacokinetics-and-immunogenicity-characteristics-of-gr2001-injection-100564947","NCT06635798","A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection","A Multicentre, Randomized, Double-blind, Human Tetanus Immunoglobulin(HTIG) Controlled Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection for Indication of Prophylaxis Against Tetanus","Inclusion Criteria:\n\n1. Chinese male or female adults aged ≥ 18 years；\n2. Participants with suspected tetanus exposure (due to dirty or contaminated wounds from various injuries);\n3. Participants who provide signed written informed consent form.\n\nExclusion Criteria:\n\n1. Participants known to be allergic to the investigational medicinal product or those suffering from severe allergic conditions；\n2. Suspect or diagnosed as tetanus;\n3. Previously diagnosed as Immunoglobulin A (IgA) deficiency with anti-IgA antibodies；\n4. Prior vaccination history of ≥ 3 doses of tetanus toxoid or tetanus toxoid- containing vaccine;\n5. Females who are pregnant or with pregnancy test positive.",{"count":249,"type":22},582,[77],"The goal of this clinical trial is to compare the efficacy and safety of GR2001 injection with Human Tetanus Immunoglobulin(HTIG) in tetanus prophylaxis. Patients will receive either GR2001 injection or HTIG on study D0.",[253],"Tetanus",[253,255,256],"Human Tetanus Immunoglobulin","GR2001 Injection","2024-10-09",{"date":259,"type":36},"2024-10-10",{"date":261,"type":36},"2024-09-03",{"date":263,"type":22},"2025-03-04",{"name":42,"class":43},20,""]